| Code | CSB-RA006163MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ADG-116, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby dampening immune responses. This inhibitory mechanism plays a fundamental role in maintaining immune homeostasis and preventing autoimmunity. Dysregulation of CTLA4 signaling is implicated in various autoimmune disorders, while its pathway is exploited by tumors to evade immune surveillance, making it a significant target in immuno-oncology research.
ADG-116 represents an investigational anti-CTLA4 antibody designed for cancer immunotherapy applications. This biosimilar antibody provides researchers with a reliable tool for studying CTLA4-mediated immune regulation, investigating T-cell co-stimulation pathways, exploring mechanisms of immune checkpoint blockade, and evaluating combination immunotherapy strategies. It supports investigations into tumor immunology, autoimmune disease mechanisms, and the development of novel therapeutic approaches targeting immune checkpoints.
There are currently no reviews for this product.